person · Reporting owner
Prichard Heather Ledbetter
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Humacyte, Inc.HUMA · Entity 6478 | Chief Operating Officer | January 21, 2025 | January 23, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Humacyte, Inc.
Report date January 21, 2025 · Filed January 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.56 · Expires 2035-01-21 | Direct | 283,101 |
Reported balance
After 2025-01-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-21 · Grant · Acquired 283,101 · Balance 283,101 F1: The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through January 21, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through January 21, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 21, 2025 Filed Jan 23, 2025 16:35 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 283,101 | $0.00 Strike: $4.56 | $0.00 |
DisclosureSEC source: 0001818382-25-000021 · wk-form4_1737668104.xml · derivative · entry 1 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283,101 Underlying: Common Stock · 283,101 shares Expires 2035-01-21 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through January 21, 2029. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 17:09 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 525 | $0.00 Strike: $10.28 | $0.00 |
DisclosureSEC source: 0001818382-24-000229 · wk-form4_1734732556.xml · derivative · entry 1 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,625 Underlying: Common Stock · 525 shares Expires 2030-12-14 F1 · derivative.exercise_date: On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vested as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application ("BLA") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021 and one-fifth of the option grant on a Form 4 filed on December 12, 2023. On December 19, 2024, Humacyte received FDA approval for its acellular tissue engineered vessel product candidate for an indication in vascular trauma. Accordingly, columns 5 and 7 of Table II report the number of securities equal to the final one-fifth of the 12/14/2020 option grant. Read SEC document |
| May 31, 2024 Filed Jun 3, 2024 16:23 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 2,625 | $9.41 | $24,706.50 |
DisclosureSEC source: 0001818382-24-000074 · wk-form4_1717446198.xml · nonDerivative · entry 6 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 16:23 UTC | Humacyte, Inc. HUMA · Entity 6478 | Exercise / conversionStock Options (right to buy) · Derivative | 48,166 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001818382-24-000074 · wk-form4_1717446198.xml · derivative · entry 8 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,834 Underlying: Common Stock · 48,166 shares Expires 2032-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 16:23 UTC | Humacyte, Inc. HUMA · Entity 6478 | Exercise / conversionStock Options (right to buy) · Derivative | 78,779 | $0.00 Strike: $2.56 | $0.00 |
DisclosureSEC source: 0001818382-24-000074 · wk-form4_1717446198.xml · derivative · entry 7 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 78,779 shares Expires 2025-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 16:23 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 48,166 | $8.32 | $400,741.12 |
DisclosureSEC source: 0001818382-24-000074 · wk-form4_1717446198.xml · nonDerivative · entry 5 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,625 F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.31 to $8.42. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 16:23 UTC | Humacyte, Inc. HUMA · Entity 6478 | Exercise / conversionCommon Stock | 48,166 | $3.07 | $147,869.62 |
DisclosureSEC source: 0001818382-24-000074 · wk-form4_1717446198.xml · nonDerivative · entry 4 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 16:23 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 78,779 | $8.36 | $658,592.44 |
DisclosureSEC source: 0001818382-24-000074 · wk-form4_1717446198.xml · nonDerivative · entry 3 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,625 F1 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.36 to $8.44. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 16:23 UTC | Humacyte, Inc. HUMA · Entity 6478 | Exercise / conversionCommon Stock | 78,779 | $2.56 | $201,674.24 |
DisclosureSEC source: 0001818382-24-000074 · wk-form4_1717446198.xml · nonDerivative · entry 2 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 16:23 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 61,941 | $7.71 | $477,565.11 |
DisclosureSEC source: 0001818382-24-000074 · wk-form4_1717446198.xml · nonDerivative · entry 1 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,625 Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 16:10 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 525 | $0.00 Strike: $10.28 | $0.00 |
DisclosureSEC source: 0001818382-23-000196 · wk-form4_1702415411.xml · derivative · entry 2 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,100 Underlying: Common Stock · 525 shares Expires 2030-12-14 F2 · derivative.exercise_date: On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application ("BLA") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021. On December 11, 2023 Humacyte submitted a BLA to the FDA. Accordingly, columns 5 and 7 of Table II report the number of securities equal to one-fifth of the 12/14/2020 option grant. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 16:10 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 290,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001818382-23-000196 · wk-form4_1702415411.xml · derivative · entry 1 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,000 Underlying: Common Stock · 290,000 shares Expires 2033-12-08 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on December 8, 2024, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2027. Read SEC document |
| May 25, 2023 Filed May 26, 2023 17:05 UTC | Humacyte, Inc. HUMA · Entity 6478 | Exercise / conversionStock Options (right to buy) · Derivative | 64,990 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001104659-23-065547 · tm2317123-10_4seq1.xml · derivative · entry 6 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,990 shares Expires 2023-11-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2023 Filed May 26, 2023 17:05 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 9,613 | $3.83 | $36,817.79 |
DisclosureSEC source: 0001104659-23-065547 · tm2317123-10_4seq1.xml · nonDerivative · entry 4 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,566 F2 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.82 to $3.89. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 25, 2023 Filed May 26, 2023 17:05 UTC | Humacyte, Inc. HUMA · Entity 6478 | Exercise / conversionCommon Stock | 64,990 | $1.19 | $77,338.10 |
DisclosureSEC source: 0001104659-23-065547 · tm2317123-10_4seq1.xml · nonDerivative · entry 3 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2023 Filed May 26, 2023 17:05 UTC | Humacyte, Inc. HUMA · Entity 6478 | Exercise / conversionStock Options (right to buy) · Derivative | 13,789 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001104659-23-065547 · tm2317123-10_4seq1.xml · derivative · entry 5 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,990 Underlying: Common Stock · 13,789 shares Expires 2023-11-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2023 Filed May 26, 2023 17:05 UTC | Humacyte, Inc. HUMA · Entity 6478 | SaleCommon Stock | 13,789 | $4.14 | $57,086.46 |
DisclosureSEC source: 0001104659-23-065547 · tm2317123-10_4seq1.xml · nonDerivative · entry 2 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,189 F1 · price: The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.14 to $4.16. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 24, 2023 Filed May 26, 2023 17:05 UTC | Humacyte, Inc. HUMA · Entity 6478 | Exercise / conversionCommon Stock | 13,789 | $1.19 | $16,408.91 |
DisclosureSEC source: 0001104659-23-065547 · tm2317123-10_4seq1.xml · nonDerivative · entry 1 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 16:06 UTC | Humacyte, Inc. HUMA · Entity 6478 | Exercise / conversionStock Options (right to buy) · Derivative | 6,564 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001818382-22-000203 · wf-form4_167096559281877.xml · derivative · entry 2 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,564 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 16:06 UTC | Humacyte, Inc. HUMA · Entity 6478 | Exercise / conversionCommon Stock | 6,564 | $1.15 | $7,548.60 |
DisclosureSEC source: 0001818382-22-000203 · wf-form4_167096559281877.xml · nonDerivative · entry 1 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 16:14 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 136,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001818382-22-000199 · wf-form4_167087964180804.xml · derivative · entry 1 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,000 Underlying: Common Stock · 136,000 shares Expires 2032-12-08 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on December 8, 2023, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2026. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:09 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 1,575 | Not disclosed Strike: $10.28 | Not disclosed |
DisclosureSEC source: 0001104659-21-110525 · tm2125954-16_4seq1.xml · derivative · entry 6 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575 Underlying: Common Stock · 1,575 shares Expires 2030-12-14 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F4 · derivative.exercise_date: Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:09 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 157,558 | Not disclosed Strike: $6.54 | Not disclosed |
DisclosureSEC source: 0001104659-21-110525 · tm2125954-16_4seq1.xml · derivative · entry 5 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,558 Underlying: Common Stock · 157,558 shares Expires 2028-04-12 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:09 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 78,779 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001104659-21-110525 · tm2125954-16_4seq1.xml · derivative · entry 4 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,779 Underlying: Common Stock · 78,779 shares Expires 2025-12-11 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:09 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 78,779 | Not disclosed Strike: $1.19 | Not disclosed |
DisclosureSEC source: 0001104659-21-110525 · tm2125954-16_4seq1.xml · derivative · entry 3 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,779 Underlying: Common Stock · 78,779 shares Expires 2023-11-22 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:09 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 6,564 | Not disclosed Strike: $1.15 | Not disclosed |
DisclosureSEC source: 0001104659-21-110525 · tm2125954-16_4seq1.xml · derivative · entry 2 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,564 Underlying: Common Stock · 6,564 shares Expires 2022-12-14 F3 · price: As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc. F2 · derivative.exercise_date: Options are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 16:09 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantCommon Stock | 2,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-110525 · tm2125954-16_4seq1.xml · nonDerivative · entry 1 Prichard Heather Ledbetter · CIK 0001877712 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,625 F1 · price: On August 26, 2021 , Alpha Health care Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub" ) and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.